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Recognition of the deleterious neurological effects of chemicals has evolved from anecdotal observation to studies of illness in persons exposed to
high doses. Now, the more subtle effects of exposures to environmental neurotoxicants are being documented: reduction in intelligence, impair-
ment in reasoning ability, shortening of attention span, and alteration of behavior. Substances to which millions of persons are exposed occupation-
ally and in the general environment that can result in such deficits include lead, organophosphorus pesticides, certain chlorinated hydrocarbons,
carbon disulfide, solvents, and mercury. The first step in the prevention of neurological impairments due to environmental exposures is to assess
the toxicity of chemicals. Fewer than 10% of the 70,000 chemicals in commercial use have been evaluated for neurotoxicity. This knowledge gap
needs to be narrowed by building on existing systems of toxicity testing. Concurrent with assessment of chemicals will be tiers of in vivo screening
tests to measure functional and structural changes following exposures in vitro. Epidemiologic surveillance of populations at high risk will continue to
inform on the ranking of suspect or known neurotoxicants. Research and researchers must become more sophisticated in the development and
application of refined biologic markers so the findings can be used to detect absorption of toxicants and early neurological or neurobehavioral dys-
function before disability occurs and to protect human health and the environment. - Environ Health Perspect 102(Suppl. 2):1 17-120 (1994).
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Introduction
While the recognition of the deleterious
neurological effects of exposure to chemi-
cals such as lead has existed since ancient
time, the scientific documentation of neu-
rologic injury following exposure to certain
chemicals arose from the study of acute ill-
ness in persons exposed to high doses of
environmental toxicants. The scenarios
leading to illnesses included: children who
ate chips of lead-based paint developed
encephalopathy; persons who consumed
wood alcohol (methanol) became blind;
exposure to organophosphorus pesticides
led to coma, convulsions, and respiratory
paralysis. Some epidemics of neurotoxic
diseases due to environmental contamina-
tion have become too well known: blind-
ness and ataxia due to consumption offish
laden with organic mercury in Minamata
Bay, Japan, and of fungicide-treated grain
in Iraq; spinal cord degeneration and
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peripheral neuropathy caused by tri-o-cre-
sylphosphate (TOCP) in cooking oil in
Morocco and in patent medicine (Ginger
Jake) in the United States: tremors, anxiety
attacks, and loss ofcoordination due to the
pesticide Kepone (chlordecone) in
Hopewell, Virginia; and the parkinsonism
caused by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a contami-
nant ofsynthetic heroin, in California and
Hawaii (1). Some are less well known and
others, such as the current outbreak in
Cuba, continue to puzzle us. Past and cur-
rent experiences that have affected tens of
thousands of persons have clearly estab-
lished that environmental chemicals can be
toxic to the nervous system, leading to neu-
rologic and psychiatric illnesses.
Injury to the nervous system due to
toxic chemicals in the environment is now
being acknowledged as an important public
health problem, yet precisely because it
remains so broadly defined, studies there-
fore remain fragmented. Part of this too
broad definition derives from the imprecise
definition of terms. In this report we too
use broad terms. "Environment" encom-
passes the wide range ofextragenetic factors
that cause injury/impairment to body sys-
tems. These factors include ambient expo-
sures (air, water, soil), diet, occupational
exposures (physical and psychosocial ele-
ments), recreational exposures (alcohol,
tobacco, drugs) among many.
"Neurotoxicology" is deemed to include
the insult(s) to any and all structures and
functions ofthe nervous systems in all their
complexity and diversity and overlap;
motor, sensory, cognition, psychological,
emotional elements, separate and conjoint.
A major question is whether any associa-
tions observed in epidemics (large or small)
reflect isolated occurrences or are manifes-
tations ofpervasive and widespread associa-
tions between toxic environmental
chemicals and neuropsychologic impair-
ment (2). The question remains central to
the issues confronting neurotoxicology
today.
Subclinical Neurotoxicity
The newly developed measurement tools
that allow detection of more subtle neuro-
logic damage add the dimension of sub-
clinical damage to the question of
chemicals in the environment exerting
dose-related adverse effects. Such subclini-
cal neurotoxic effects can include lower
intelligence, impaired reasoning ability,
shorter attention span, alterations in behav-
ior. Although subtle in appearance, the
changes following exposure to lead, mer-
cury, organophosphorus pesticides, some
chlorinated hydrocarbons, and solvent mix-
tures, can be devastating in effect. Because
the central nervous system has little capac-
ity for repair, the damage can be irre-
versible. The recognition of subclinical
Environmental Health Perspectives 117LANDRIGANETAL.
neurotoxicity raises the possibility that some
fraction of neurologic and psychiatric ill-
ness, such as parkinsonism, motor neuron
disease, demyelinating illness, and some
forms of dementia can be exacerbated and
possibly caused by chronic, low level expo-
sure to environmental neurotoxicants (3).
Biologic Markers in
Neurotoxicity
Recent reports in environmental health
research have defined biologic markers as
indicators of events or conditions in bio-
logic systems or samples (4,5). They are
most easily classified as markers of expo-
sure, of effect, and of susceptibility. A
marker of exposure is an exogenous sub-
stance, its metabolite, or the product of its
interaction with some molecule or cell as
measured in an organism. A marker of
effect is a measurable biochemical, physio-
logic or other alteration within an organ-
ism that can indicate potential or
established impairment. A marker of sus-
ceptibility is that indicator of variation
(inherent or acquired) in an organism's
response when challenged by exposure to a
specific substance (5,6). The development
and application ofbiologic markers ofneu-
rotoxicity are needed to augment the sensi-
tivity and specificity of other studies.
Measurements of specific lipids and pro-
teins or of neurotransmitters or their
metabolites, as well as measurement of
changes in the number or affinity of spe-
cific neurotransmitter receptors, are some
biochemical markers of neurologic func-
tion. Structural markers can be studied in
tissues obtained at biopsy. Gaining this
edge in identifying early and subclinical
neurotoxic injury would allow intervention
when dysfunction might still be halted,
when impairment in others so exposed
could be prevented. In epidemiological and
clinical studies, validated biologic markers
would allow the systematic monitoring of
populations at high risk and enhance the
findings from other disciplines. Tests that
appear to provide reliable and sensitive
information on early injury are becoming
more sophisticated and gaining wide appli-
cation (7). The development and increased
use of biologic markers of neurotoxic sub-
stances in human studies will permit pre-
cise delineation ofindividual exposures and
the detailed assessment of dose-response
relationships (8).
Neurotoxicity Testing
Although about 70,000 chemicals are in
commercial use, very few have been evalu-
ated. Other than pharmaceuticals, fewer
than 1/10 of chemicals in commerce have
been tested for neurotoxicity, and fewer yet
have been thoroughly studied. Since it is
unknown how many may be neurotoxi-
cants, it is possible that large numbers of
people are exposed to these potential haz-
ards and may be suffering unrecognized
injury as a result.
Closing this gap in knowledge and toxi-
city testing must be the essential first step
in the prevention of environmental neuro-
toxicity. The dearth of information and
resources precludes any across the board
testing ofall chemicals. New strategies will
need to include: the identification ofthose
chemicals most likely to be hazardous and
to which large numbers of persons are
exposed; the setting ofpriorities for testing
the more ubiquitous substances; the refine-
ment ofexisting neurotoxicity test systems;
the development and validation ofefficient,
sensitive new testing systems; and the stan-
dardization ofapproaches to the interpreta-
tion/significance ofthe findings.
This strategy for neurotoxologic assess-
ment will extend currently available tests
systems (9) based on a tiered structure.
Data from the initial, screening, tier will
guide decisions to test chemicals at the
higher tiers, as well as decisions concerning
types of testing. The screening tier will
consist of a set of tests to measure chemi-
cal, structural, and functional changes in an
integrated fashion, in addition to a func-
tional observational battery. Such tests will
need to be carefully validated at every stage.
To address the broad functional diversity
(motor, sensory, learning and memory) of
the nervous system, the tests must examine
multiple end points: a highly specific effect
on one function ofthe nervous system will
not necessarily entail an effect on another.
The development of rapid and economical
approaches will do much to overcome the
drain of the current labor- and resource-
intensive testing systems.
While in vitro systems are available and
appear suitable for detailed studies ofsome
neurotoxic mechanisms, they have not
been used for screening. A recognized
stumbling block is the establishment of a
relationship between effects observed and
the expression of effects at a structural or
behavioral level in whole animals, particu-
larly in humans. It is essential that such
studies of the correlation between the
results of in vitro systems and the findings
offunctional in vivo tests be conducted. In
vitro assays and in whole animals should be
conducted conjointly to determine the cor-
respondence between the two types of
assays. This could validate the use of in
vitro assays as quicker, more efficient meth-
ods for screening chemicals for neurotoxic-
ity, and allow a better understanding ofthe
mechanisms ofneurotoxic damage. Studies
of neurotoxic reactions at the molecular
and cellular levels might also be used to
generate the more detailed mechanistic
information necessary for accurate risk
assessment and for development and evalu-
ation of reliable structure-activity relation-
ships.
In both in vivo and in vitro neurotoxic-
ity testing, the general objective is to iden-
tify neurotoxic potential before the
occurrence ofhuman exposure. The goal is
the prevention ofhuman disease.
Epidemiologic Studies and
Neurotoxicology
In order to provide additional information
on the human neurotoxic effects of envi-
ronmental chemicals and to complement
screening studies in vitro and in animals,
epidemiologic and clinical studies ofpopu-
lations exposed to potentially neurotoxic
chemicals are needed. High-risk popula-
tions must be identified and monitored.
Currently, public health surveillance sys-
tems for the detection of people who are
potentially exposed to environmental neu-
rotoxicants are not well developed. There is
little information on the background inci-
dence and prevalence of the major neuro-
logic diseases in the American population
(10). The evaluation of persons diagnosed
with neurologic illnesses to elicit any possi-
ble environmental etiologies would be very
informative.
Ascertainment of the neurotoxic effects
of exposure to environmental chemicals
through epidemiologic and clinical studies
continues to be complicated by the very
complexity, variety and subtlety ofthe pos-
sible reactions of the nervous system.
Reactions to toxic insult can be as varied as
peripheral neuropathy, alterations in the
sense of taste or smell, or impaired mathe-
matical ability. Months and years can pass
between exposure and the appearance of
dysfunction and disease. The subclinical
changes are often subtle, unappreciated by
either the subject or coworkers/family.
Therefore, populations known to have
been exposed to potential neurotoxicants
should be followed for long periods in
prospective studies; in retrospective studies
ofpersons with neurologic illness, the pos-
sibility that exposures may have occurred
many years earlier must be kept in mind.
Increasingly, epidemiologic studies will
need to utilize biologic markers of expo-
sure, oftoxic effects, and ofsusceptibility.
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Risk Assessment and
Neurotoxicology
Estimating the risks to humans associated
with exposure to toxic chemicals in the envi-
ronment most often involves extrapolation
from high experimental doses used in ani-
mal tests to lower environmental doses.
Gaps in available scientific data are bridged
with numerous assumptions. Such risk
assessment techniques have usually be
applied to cancer as an end point, and tech-
niques for assessing other types of risk are
just now beginning to be developed (11).
The current approach in estimating non-
cancer end points, simply dividing the dose
below which effects were not seen by uncer-
tainly factors to generate a presumably safe
exposure level, must be considered inade-
quate. Virtually all neurotoxicologic risk
assessment today is limited to qualitative
hazard identification and to the early stages
ofhazard characterization. Sufficient data or
adequate paradigms are not yet available to
permit quantitative evaluation of most neu-
rotoxic risks.
Risk-assessment techniques that incor-
porate more quantitative information about
dose-time-response relationships and mech-
anisms oftoxicity are being developed. They
will assist in assessing the benefits to human
populations gained from reducing exposures
to neurotoxic agents. The construction of
new models for neurotoxicologic risk assess-
ment upon the diverse susceptibilities ofvar-
ious individuals and populations will be
facilitated by the acquisition of knowledge
ofthe fundamental mechanisms ofaction of
chemical toxicants on the human nervous
system. How environmental chemicals cause
injury will need to be delineated at the mol-
ecular and subcellular level (12). Such infor-
mation will then allow much improved
prediction and quantitation of the risks
whose effects become evident only many
years later.
Conclusions
Exposure to chemical agents in the envi-
ronment can lead to neurotoxic impairment
and illness. This has been demonstrated fol-
lowing exposure to many different agents
and in individuals and in epidemics.
Neurotoxicity caused by environmental tox-
icants ranges from neurologic to psychiatric
disorders, from devastating illnesses, such as
parkinsonism and dementia, to subtle
changes in behavior and limitations on
memory and cognition. The complexity of
the disorders reflects the enormous diversity
of the nervous system's functions and the
large number ofcellular and subcellular tar-
gets. Greatest concern surrounds the fact
that some damage in the brain can be irre-
versible and permanent, and that in addition
to immediate effects, many neurotoxic
effects become evident only after long latent
periods. Chemicals can permanently alter
brain development, can cause sublicinical
dysfunction, or reduce reserve capacity of
the nervous system. On the basis ofavailable
evidence, it is not unreasonable to hypothe-
size that a definite, but as yet unspecified,
fraction of human neurologic and psychi-
atric disease is attributable to chemical
agents in the environment.
The lack of quantitative or qualitative
information on possible adverse effects of
most chemicals in commercial use is a major
obstacle to assessing the contribution of
environmental chemicals to the causation of
nervous system disease and dysfunction.
While some chemicals are known to have
neurotoxic potential, there is a particular
lack of data on chronic and long-latency
neurotoxic effects. Though widely used as
an approach in assessment oftoxicity, struc-
ture-activity relationships are less than opti-
mal for predicting neurotoxic potential;
greater fundamental understanding of
mechanisms should lead to more useful
applications ofSARs.
The development and application of
biologic markers are needed for the assess-
ment ofsubclinical neurotoxic effects. Such
markers can be developed through in vitro
analyses, through animal studies, or during
observational studies in human populations.
While associations between biologic markers
and disease are usually established in cross-
sectional studies, a particular need to vali-
date putative biologic markers in prospective
studies exists. Only in longitudinal prospec-
tive studies of populations exposed to sus-
pect or known neurotoxicants can the
reliability of the biologic markers be accu-
rately assessed and their predictive signifi-
cance evaluated.
Current testing systems can be expanded
using a tiered approach. The first tier, or
screen, is intended for hazard identification.
These findings and the patterns ofexposure
of the chemical would determine further
characterization of dose-response (second
tier) and mechanism (third tier). Since there
is no existing validated system that satisfies
all the necessary requirements for a screen-
ing program, the range ofany newly devel-
oped program should extend to the
detection of neurodevelopmental effects, of
effects on cognitive function, and of neu-
roendocrine effects. Work has yet to be
done to determine the predictive ability of
individual screening tests; the relationship
between test results and data from long-term
studies in animals or epidemiologic and
clinical studieswill need to bevalidated.
There have been only limited attempts
to quantify the exposure ofpopulations to
neurotoxic chemicals. Clinical evaluations in
populations at risk for neurotoxicity have
been inadequate and fragmented. The possi-
bility that developmental delays in the
young and some forms of dementia and
parkinsonism in the elderly might have an
environmental etiology is only now becom-
ing to be appreciated.
Delay in recognition of the possible
environmental origin ofneurologic and psy-
chiatric disease derives from inadequate
incorporation of the elements of environ-
mental and occupational medicine into the
training of most physicians, toxicologists,
epidemiologists, risk assessors and other
health providers. Greater uniformity and
precision in disease definition would
improve the identification of diseases of
neurologic interest.
The commonly used paradigms for risk
assessment are inadequate to model the risks
associated with exposure to neurotoxicants.
The neurotoxicologic risk assessments, that
have been largely limited to the application
of no-observed-effect levels and uncertainty
factors, cannot accurately encompass the
diversity of neurologic responses to injury;
they cannot (as yet) generate risks estimates
that are applicable to the multitudes and
magnitudes ofexposures.
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